Compare Amgen, Inc. (AMGN) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Cognizant Technology Solutions Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Cognizant Technology Solutions Corp trades at $42.9 (market cap $20.13B). The key difference: Amgen, Inc. is far larger — about 9.7× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| AMGN | CTSH | |
|---|---|---|
Market Cap | $196.12B | $20.13B |
Sector | Health | Technology |
52-Week High | $388.16 | $86.70 |
52-Week Low | $271.18 | $38.73 |
Enterprise Value | $241.41B | $19.71B |
Dividend Yield | 2.77% | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CTSH trades at $42.57, down 1.91% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 9.23 and consistent earnings beats. Recent news highlights AI partnerships with Google Cloud and OpenAI, while cash flow improved in 2025 to $403M. The stock faces near-term pressure from weak demand and competition, but analyst consensus targets $64.33.
The outlook balances attractive valuation against sector rotation headwinds. Opportunities include AI-driven growth and shareholder returns via dividends, but risks involve margin pressure and technical resistance near $44. Wall Street sentiment is mixed with 43% buy ratings, suggesting cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
